-
New research offers hope in multiple myeloma treatment through enhanced NK cell function
24 Apr 2024 08:51 GMT
… availability of treatments like immunomodulators, proteasome inhibitors, and monoclonal antibodies, multiple myeloma remains … with an unnamed biotech company developing antibodies, the team introduced a …
-
European Commission Approves Janssen and Legend Biotech’s Carvykti for Expanded Indication in Earlier Line Multiple Myeloma
24 Apr 2024 03:33 GMT
… from the CARTITUDE-4 clinical trial (NCT04181827), a phase 3, randomized … second-line treatment of patients with relapsed and refractory multiple myeloma. News release … U.S. FDA for patients with relapsed or refractory multiple myeloma who have …
-
Orphan drug market to reach $270B by 2028, led by J&J, Vertex and Roche: Evaluate
24 Apr 2024 04:48 GMT
… pharmaceutical market with booming sales. But thanks to blockbuster meds … drug’s shine, such as the “blazing return of big drugs … Johnson & Johnson’s multiple myeloma blockbuster Darzalex, Vertex’s … UCB’s two new treatment options, Zylbrysq and Rystiggo …
-
New study points to racial and social barriers that block treatment for multiple myeloma
23 Apr 2024 23:04 GMT
… marrow transplant treatment to halt the progression of multiple myeloma.
An … a greater risk of developing the cancer than other … is Multiple myeloma and how is its treated?
Multiple myeloma is a … Transplant Over time in Multiple Myeloma: A Population-Based …
-
CARVYKTI becomes first BCMA-targeted treatment approved by European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
23 Apr 2024 12:44 GMT
… 2022. Most patients with multiple myeloma relapse after standard treatment. Each additional line … eligible patients with multiple myeloma, who may now benefit from treatment with cilta … and Drug Administration (FDA) approval of cilta-cel for the treatment of …
-
Pharmac proposes to fund new blood cancer multiple myeloma drug pomalidomide
23 Apr 2024 05:15 GMT
… Pharmac’s proposal to fund a new drug for the blood cancer multiple myeloma … by treatment and medicines.
Each combination of drugs eventually … being released and developed.
New Zealanders have … lack of funded medications for multiple myeloma patients.
One …
-
More Treatment Options Proposed For People With Multiple Myeloma And Myelodysplastic Syndrome
23 Apr 2024 01:55 GMT
…
for treating multiple
myeloma
Carfilzomib
Pharmac
is considering three funding
applications for carfilzomib to treat multiple myeloma …
applications for daratumumab for the treatment of
multiple myeloma. There are three applications …
-
Approved Bispecifics for the Treatment of Relapsed/Refractory Multiple Myeloma (R/R MM)
22 Apr 2024 17:42 GMT
-
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
22 Apr 2024 17:26 GMT
… the treatment paradigm for patients battling multiple myeloma by … with medications used for the treatment of … Drug Administration (FDA) under the brand name CARVYKTI® for the treatment … development of new pharmaceutical products; unexpected clinical trial …
-
NICE backs wider NHS use of multiple myeloma drug Nexpovio
22 Apr 2024 14:33 GMT
… the back of the BOSTON trial, which showed an improvement in … -free survival (PFS) with the drug compared with Velcade plus dexamethasone … defence mechanisms.”
Despite advances in treatment, multiple myeloma remains incurable in the majority …